CDSCO introduces SHRESTH index to improve performance of state drug regulatory authorities: Shardul Nautiyal, Mumbai Saturday ...
US FDA accepts Viatris’ sNDA of MR-141 to review for treatment of presbyopia: Pittsburgh Saturday, February 28, 2026, 12:00 Hrs [IST] Viatris Inc, US-headquartered global health ...
Ultima Genomics, Hamilton partner to enable improved lab operations to drive sequencing at scale: Fremont, California Saturday, February 28, 2026, 11:00 Hrs [IST] Ultima Genomics, ...
Quotient Sciences extends commercial manufacturing partnership with Ipsen for an ultra-rare disease treatment: Philadelphia, Pennsylvania Saturday, February 28, 2026, 10:00 Hrs [I ...
India’s neurodevelopment care sees decisive shift toward structured, evidence-based informed pathways: Nitin Bindlish: Nandita Vijayasimha, Bengaluru Saturday, February 28, 2026 ...
TN, Karnataka, Rajasthan declare highest number of NSQs in January: Gireesh Babu, New Delhi Saturday, February 28, 2026, 08:00 Hrs [IST] Around 29% of the total Not of Standard Qu ...
DoP amends NIPERs Council Rules to enable chairperson to take action in emergency situations: Gireesh Babu, New Delhi Saturday, February 28, 2026, 08:00 Hrs [IST] The Department o ...
TNCDA escalates battle against rapid medicine delivery and illegal e-pharmacies: Peethaambaran Kunnathoor, Chennai Saturday, February 28, 2026, 08:00 Hrs [IST] The Tamil Nadu Chem ...
China NMPA accepts for priority review GSK’s NDA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Friday, February 27, 2026, 14: ...
IDEAYA Biosciences begins patient enrolment in phase 1 trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC: South San Francisco, California Friday, February 27, 2026 ...
US FDA accepts Vanda Pharmaceuticals’ BLA for imsidolimab to treat Generalized Pustular Psoriasis: Washington Friday, February 27, 2026, 17:00 Hrs [IST] Vanda Pharmaceuticals In ...